MX2022016236A - Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. - Google Patents

Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.

Info

Publication number
MX2022016236A
MX2022016236A MX2022016236A MX2022016236A MX2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A
Authority
MX
Mexico
Prior art keywords
methods
spectrum disorder
neuromyelitis optica
optica spectrum
treating
Prior art date
Application number
MX2022016236A
Other languages
English (en)
Spanish (es)
Inventor
William Rees
Michael Smith
Eliezer Katz
Nanette Mittereder
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2022016236A publication Critical patent/MX2022016236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2022016236A 2020-06-30 2021-06-30 Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. MX2022016236A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US202063071092P 2020-08-27 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
MX2022016236A true MX2022016236A (es) 2023-03-29

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016236A MX2022016236A (es) 2020-06-30 2021-06-30 Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.

Country Status (11)

Country Link
US (1) US20230406928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172211A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534916A (cg-RX-API-DMAC7.html)
KR (1) KR20230030642A (cg-RX-API-DMAC7.html)
CN (1) CN116234571A (cg-RX-API-DMAC7.html)
AU (1) AU2021299307A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178954A1 (cg-RX-API-DMAC7.html)
IL (1) IL299381A (cg-RX-API-DMAC7.html)
MX (1) MX2022016236A (cg-RX-API-DMAC7.html)
WO (1) WO2022006283A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900888B2 (ja) * 2020-10-29 2026-08-05 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101977843B1 (ko) * 2017-02-16 2019-05-13 국립암센터 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용
CN110522908A (zh) * 2018-05-25 2019-12-03 荣昌生物制药(烟台)有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
JP7900888B2 (ja) * 2020-10-29 2026-08-05 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用

Also Published As

Publication number Publication date
BR112022026747A2 (pt) 2023-01-24
WO2022006283A2 (en) 2022-01-06
CA3178954A1 (en) 2022-01-06
KR20230030642A (ko) 2023-03-06
EP4172211A4 (en) 2024-07-10
EP4172211A2 (en) 2023-05-03
US20230406928A1 (en) 2023-12-21
WO2022006283A3 (en) 2022-02-03
AU2021299307A1 (en) 2022-12-22
IL299381A (en) 2023-02-01
CN116234571A (zh) 2023-06-06
JP2023534916A (ja) 2023-08-15

Similar Documents

Publication Publication Date Title
EP3878862A3 (en) Anti-coronavirus antibodies and methods of use
WO2022006283A3 (en) Methods of treating neuromyelitis optica spectrum disorder
MX2022016061A (es) Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
MX2022002682A (es) Anticuerpos anti-cd73.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BRPI0515884A (pt) métodos de diagnóstico e tratamento de complicações da gravidez
EA202190841A1 (ru) Композиции для снижения уровней мочевой кислоты в сыворотке крови
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
WO2020185541A3 (en) Zilucoplan as deep tissue penetrating c5 inhibitor
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
MX2022011050A (es) Anticuerpos anti-cd36 y su uso para tratar cancer.
MX2022015772A (es) Proteínas enpp1 o enpp3 solubles y sus usos.
EA202193111A1 (ru) Композиции и способы для лечения рака
WO2021257816A3 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
WO2019241730A8 (en) Increasing immune activity through modulation of postcellular signaling factors
MX2025008918A (es) Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение
MA47550B2 (fr) Systèmes et procédés de préparation de boissons contenant de l'éthanol
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
EA202090427A1 (ru) Композиции и способы лечения атопического дерматита и выбора лечения
ZA202107917B (en) Methods of treating borderline personality disorder
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2024008767A (es) Agente de union de acido polisialico de-n-acetilado (dpsa) y metodo de uso del mismo.
MX2025008198A (es) Terapia con moléculas de proteínas de unión a lípidos